Self-injected contraceptives
Does the investment reflect women’s preferences
Bibliographic Data
| ID | 21879020 |
|---|---|
| Authors | Shannon N Wood (0000-0003-4389-3526, Johns Hopkins University, corresponding author), Sophia Magalona (0000-0003-2050-9376, Johns Hopkins University), Linnea A Zimmerman (0000-0002-0118-0889, Johns Hopkins University), Funmilola M Olaolorun (0000-0001-5544-2875, University of Ibadan), Funmilola Olaolorun (University of Ibadan), Elizabeth Omoluabi (0000-0003-1754-5384, University of the Western Cape), Pierre Akilimali (0000-0002-3828-6214, Ministry of Public Health), Georges Guiella (0000-0001-8525-340X, Université Joseph Ki-Zerbo), Peter Gichangi (0000-0001-9636-165X, International Centre for Reproductive Health Kenya), Philip Anglewicz (0000-0002-7967-3843, Johns Hopkins University) |
| Year | 2022 |
| Volume | 7 |
| Issue | 7 |
| Pages | e008862 |
| Publication date | 2022-07-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2022-008862 |
| PMID | 35835480 |
| OpenAlex | W4285403273 |
| Language | EN |
| Citations received | 3 |
| References cited | 26 |
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs
Developing country · Economic growth · Economics · Environmental health · Family planning · Gynecology · Medroxyprogesterone acetate · Population · Research methodology · Socioeconomics · Sociology · Adolescent Sexual and Reproductive Health · Global Maternal and Child Health · Medicine · Reproductive Health and Contraception
Women's Perspectives on the Unique Benefits and Challenges of Self‐Injectable Contraception
Understanding clients’ and providers’ perspectives on the implementation of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) for self-injection programming in Nigeria
The case for investing in provider-administered subcutaneous DMPA
| Unique citing works | 3 |
|---|---|
| Citations per year | 1,5 |
| Citation span | 2024 - 2026 (3) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 2 |